C
코아스템켐온
166480KOSDAQ의약품 제조업40.8 / 100
Reference Date: 2026-07-24
Financial Score4.5 / 40
News Sentiment21.3 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 16.1% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
CoaStemKemOn focuses on developing and selling stem cell therapies, with its product 'NeuroNata-Al' for Lou Gehrig's disease commercialized since 2015. The company merged with KemOn, a top non-clinical CRO firm in South Korea, in 2022 to enhance R&D capabilities, and approximately 98% of its revenue comes from non-clinical research services.
Number of Employees
321people
Average Salary
48.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 11.234.0Point
PBR
1.77Industry Average 0.810.0Point
2.2x industry avg (risky)
ROE
-51.72Industry Average 4.010.0Point
Well below industry avg
Debt Ratio
36.21Industry Average 12.430.0Point
2.9x industry avg (risky)
Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼22.2% (2-year basis)
Operating Profit Growth Rate
0.5 / 3
Avg ▼4.1% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -63.1% (improving, 3yr)
Detailed News Sentiment
1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85
- Positive코아스템켐온, '뉴로나타-알' 美 FDA 허가 정조준…"체질개선 본격화...
코아스템켐온의 ALS 치료제 '뉴로나타-알주'가 FDA 허가를 향해 나아가며 글로벌 시장 진출과 CRO 경쟁력 강화로 긍정적인 체질 개선이 예상된다.
Detailed Momentum
52-week position3.0Point
52w lower range (21%)
Current 1,846Won52-week high 4,80052-week low 1,060
1-month return0.0Point
1m -16.09% (strong drop)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-08